The latter showed that the addition of quizartinib to standard chemotherapy with or without alloSCT followed by maintenance therapy for up to 3 years resulted in improved OS in adults aged 18–75 years with FLT3-ITD-positive AML (93). Here, FLT3 is linked to acute myeloid leukemia.